Biopharma Dealmaking In 2023: The Story So Far

Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn and above all else, discover the new opportunities and potential partnerships that will deliver the innovations of the future. In short, to make new deals. The challenging economy and the associated […]

Share:

Download today








Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn and above all else, discover the new opportunities and potential partnerships that will deliver the innovations of the future. In short, to make new deals.

The challenging economy and the associated state of the stock markets has made the last 18 months tough for players of every size in the industry. But are we about to turn a corner?

Download now to read Evaluate’s latest market report.Biopharma-Dealmaking-2023-Story-So-Far-featured-image

 

 

Upcoming Webinar

China Pipelines, Western Portfolios

Tuesday 14th July 3pm BST | 10am ET

Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.

Related Content